Meta-analysis of everolimus-eluting stents versus first-generation drug-eluting stents in patients with left main coronary artery undergoing percutaneous coronary intervention

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 1718-1719

  Capodanno, Davide ^a   Capranzano, Piera ^a   La Manna, Alessio ^a   Tamburino, Corrado ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Everolimus eluting stents; Left main coronary artery; Percutaneous coronary intervention

Indexed keywords

EVEROLIMUS; PACLITAXEL;

ADULT; AGED; CAUSE OF DEATH; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LEFT CORONARY ARTERY; LETTER; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

EVEROLIMUS-ELUTING STENTS; LEFT MAIN CORONARY ARTERY; PERCUTANEOUS CORONARY INTERVENTION;

CORONARY ARTERY BYPASS; CORONARY VESSELS; DRUG-ELUTING STENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS;

EID: 84885324573     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.03.135     Document Type: Article

References (9)

1. Capodanno D, Stone GW, Morice MC, Bass TA, Tamburino C. Percutaneous coronary Intervention versus coronary artery bypass graft surgery In left main coronary artery disease: a meta-analysis of randomized clinical data. J Am Coll Cardiol 2011;58:1426-32.
2. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402.
3. deWaha A, Cassese S, Park DW, Burzotta F, et al. Everolimus-eluting versus sirolimuseluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol 2012;101:461-7.
4. Valenti R, Migliorini A, Parodi G, et al. Clinical and angiographic outcomes of patients treatedwith everolimus-eluting stents or first-generation Paclitaxel-eluting stents for unprotected left main disease. J Am Coll Cardiol 2012;60:1217-22.
5. KimYH, Park DW, Ahn JM, et al. Everolimus-eluting stent Implantation for unprotected left main coronary artery stenosis. The PRECOMBAT-2 (Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent In patients with Left Main Coronary Artery disease) study. JACC Cardiovasc Interv 2012;5:708-17.
6. De la Torre Hernandez JM, Alfonso F, Recalde AS, et al. Comparison of paclitaxeleluting stents (Taxus) and everolimus-eluting stents (Xience) In left main coronary artery disease with 3 years follow-up (from the ESTROFA-LM Registry). Am J Cardiol 2013 Mar 1;111:676-83.
7. Moschovitis A, Stefanini GG, Magro M, et al. The Impact of left main disease on longterm clinical outcomes among patients treated with the unrestricted use of everolimus-, sirolimus-, and paclitaxel-eluting stents. a substudy of the Bern-Rotterdam Registry. Presented at Transcatheter Cardiovascular Therapeutics In Miami (FL); October 2012.
8. Mehilli J. Zotarolimus-vs. everolimus-eluting stents for treatment of unprotected left main coronary artery lesions. Presented at Transcatheter Cardiovascular Therapeutics In Miami (FL); October 2012.
9. Capodanno D, Tamburino C. Unraveling the EXCEL: promises and challenges of the next trial of left main percutaneous coronary Intervention. Int J Cardiol 2012;156:1-3.